Genetic Determinants of Opioids Analgesia
Information source: Hadassah Medical Organization
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Nephrolithiasis
Intervention: Alfentanil (Drug)
Phase: N/A
Status: Completed
Sponsored by: Hadassah Medical Organization Official(s) and/or principal investigator(s):
Yoseph Caraco, MD, Principal Investigator, Affiliation: Hadassah Medical Organization, Jerusalem, Israel
Summary
The response to opioids varies greatly among individuals. Some of these variability is
accounted for by genetic factors.
The present study was designed to evaluate the possibility that genetic polymorphism in the
gene encoding for mu opioid receptor may explain variability in the response to alfentanil
during lithotripsy.
Clinical Details
Official title: The Effect of mu Opioid Receptor Polymorphism on the Response to Alfentanil During Lithotripsy
Study design: Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Primary outcome: Total alfentanil dose used during the procedure.The extent of respiratory depression.
Eligibility
Minimum age: 20 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Age > 20
Exclusion Criteria:
- Regular use of opioid drugs
- Known hypersensitivity to alfentanil
Locations and Contacts
Hadassah Medical Organization, Jerusalem, Israel
Additional Information
Starting date: August 1997
Last updated: March 17, 2008
|
